Cardio-oncology and chemotherapy-induced cardiotoxicity
Research activity includes the prevention and monitoring of cardiac toxicity associated with cancer treatment, with particular interest in patients with breast cancer receiving therapies that may affect left ventricular function and broader cardiovascular safety.
- SGLT-2 inhibitors
- cardiotoxicity surveillance
- breast cancer care
The clinical focus extends to identifying strategies that reduce treatment-related myocardial injury and preserve cardiac performance during oncologic therapy.
Chronic Obstructive Pulmonary Disease and acute respiratory failure
The sponsor supports studies in COPD, especially hospitalised exacerbations complicated by acute respiratory failure or acute-on-chronic respiratory failure, with interest in inflammatory pathways and respiratory stabilisation.
- COPD exacerbation
- acute respiratory failure
- inflammatory biomarkers
Attention is directed toward pulmonary inflammation, gas exchange impairment, and the management of severe respiratory deterioration requiring inpatient care.
Non Small Cell Lung Cancer and thoracic oncology
Clinical research activity covers NSCLC, including locally advanced disease, with interest in combined immunotherapy, radiotherapy, and multimodal cancer treatment approaches in thoracic malignancy.
- non-small cell lung cancer
- thoracic oncology
- immunotherapy
This area reflects involvement in treatment strategies for lung cancer that aim to improve disease control while integrating systemic and local therapies.
Electrical storm and complex arrhythmia management
Another area of interest is severe ventricular arrhythmia, particularly electrical storm, with evaluation of interventions used to suppress recurrent malignant rhythm disturbances in acute settings.
- ventricular arrhythmia
- electrical storm
- acute arrhythmia treatment
The research emphasis includes rapid rhythm control, prevention of recurrent shock-requiring arrhythmias, and management of high-risk electrophysiological instability.
